《復牌表現》澳優(01717.HK)強勢反駁沽空機構所有指控股價曾彈17%成交急增
遭沽空機構狙擊的澳優(01717.HK)發聲明強勢反駁沽空機構殺人鯨資本(Blue Orca)所有指控,針對該沽空機構指控的誇大收入和盈利、低報員工成本、羊奶粉成份誤導消費者,以及進行未披露的關聯方交易等均一一予以駁斥,並稱公司所有嬰幼兒奶粉產品進口數據均可由中國海關總署發出官方文件支持等。澳優將保留對殺人鯨資本或須對作出無根據指控而負責之各方採取法律行動權利。
該股繼昨日挫20%中途停牌後,今天復牌由五個月低位重越牛熊線(10.78元),最多彈17%高見11.42元,現造11.06元,彈14%,成交急增至4,949萬股,創逾九個高,涉資5.43億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.